Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer: an Open-label, Multi-center Trial

NCT05880927 is registered in ClinicalTrials.gov with Taizhou Hospital as lead sponsor.

NCT NCT05880927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05880927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer: an Open-label, Multi-center Trial
Lead sponsor
Taizhou Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
January 1, 2019
Completion date
December 31, 2025
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer